Cliff Asness’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$295M Sell
546,002
-280,224
-34% -$158M 0.1% 272
2026
Q1
$486M Sell
826,226
-455,473
-36% -$227M 0.22% 93
2025
Q4
$625M Buy
1,281,699
+295,221
+30% +$137M 0.33% 51
2025
Q3
$414M Sell
986,478
-286,683
-23% -$96.4M 0.27% 69
2025
Q2
$363M Buy
1,273,161
+364,713
+40% +$109M 0.3% 60
2025
Q1
$273M Sell
908,448
-66,996
-7% -$23M 0.28% 71
2024
Q4
$344M Buy
975,444
+7,710
+0.8% +$2.83M 0.44% 25
2024
Q3
$347M Buy
967,734
+248,224
+34% +$83.8M 0.48% 23
2024
Q2
$229M Sell
719,510
-127,445
-15% -$33.7M 0.35% 51
2024
Q1
$195M Buy
846,955
+295,188
+53% +$66.6M 0.33% 65
2023
Q4
$121M Buy
551,767
+75,179
+16% +$17.3M 0.23% 99
2023
Q3
$108M Sell
476,588
-34,013
-7% -$7.83M 0.22% 101
2023
Q2
$112M Buy
510,601
+137,378
+37% +$30.4M 0.24% 95
2023
Q1
$82.4M Buy
373,223
+113,214
+44% +$27.9M 0.18% 131
2022
Q4
$71.3M Sell
260,009
-34,079
-12% -$8.6M 0.16% 153
2022
Q3
$61.3M Sell
294,088
-58,990
-17% -$13.2M 0.15% 164
2022
Q2
$83.2M Sell
353,078
-23,313
-6% -$4.74M 0.19% 132
2022
Q1
$66.1M Sell
376,391
-25,645
-6% -$4.89M 0.13% 195
2021
Q4
$86.9M Sell
402,036
-49,571
-11% -$9.73M 0.16% 148
2021
Q3
$83.4M Sell
451,607
-55,171
-11% -$10.9M 0.15% 160
2021
Q2
$89.6M Sell
506,778
-120,489
-19% -$22.9M 0.16% 158
2021
Q1
$105M Buy
627,267
+3,071
+0.5% +$512K 0.17% 136
2020
Q4
$94.7M Sell
624,196
-318,854
-34% -$41.8M 0.17% 136
2020
Q3
$95.2M Buy
943,050
+11,178
+1% +$1.23M 0.16% 147
2020
Q2
$113M Buy
931,872
+57,566
+7% +$6.48M 0.18% 129
2020
Q1
$82.9M Buy
874,306
+203,177
+30% +$19.3M 0.14% 174
2019
Q4
$58.6M Buy
671,129
+133,916
+25% +$11.8M 0.07% 356
2019
Q3
$42.8M Sell
537,213
-593,931
-53% -$47.8M 0.05% 410
2019
Q2
$87.6M Sell
1,131,144
-1,358,074
-55% -$127M 0.1% 240
2019
Q1
$292M Sell
2,489,218
-25,345
-1% -$2.95M 0.31% 89
2018
Q4
$274M Buy
2,514,563
+187,196
+8% +$21.7M 0.32% 82
2018
Q3
$298M Buy
2,327,367
+235,459
+11% +$29.1M 0.28% 88
2018
Q2
$237M Buy
2,091,908
+269,437
+15% +$29.6M 0.24% 109
2018
Q1
$205M Sell
1,822,471
-110,571
-6% -$14M 0.22% 113
2017
Q4
$286M Sell
1,933,042
-246,958
-11% -$31.4M 0.3% 85
2017
Q3
$258M Sell
2,180,000
-9,201
-0.4% -$1.18M 0.31% 83
2017
Q2
$284M Buy
2,189,201
+452,844
+26% +$56.5M 0.38% 61
2017
Q1
$235M Buy
1,736,357
+377,395
+28% +$57.2M 0.31% 77
2016
Q4
$195M Sell
1,358,962
-224,895
-14% -$28.7M 0.27% 84
2016
Q3
$187M Sell
1,583,857
-256
-0% -$30.8K 0.29% 76
2016
Q2
$168M Buy
1,584,113
+277,266
+21% +$30.9M 0.3% 76
2016
Q1
$146M Sell
1,306,847
-481,925
-27% -$61M 0.26% 100
2015
Q4
$280M Buy
1,788,772
+485,617
+37% +$70.7M 0.49% 31
2015
Q3
$171M Buy
1,303,155
+446,846
+52% +$71.7M 0.34% 66
2015
Q2
$149M Buy
856,309
+54,920
+7% +$9.88M 0.3% 87
2015
Q1
$138M Sell
801,389
-70,166
-8% -$10.7M 0.32% 83
2014
Q4
$113M Buy
871,555
+322,511
+59% +$41.6M 0.24% 122
2014
Q3
$70.6M Buy
549,044
+35,200
+7% +$3.63M 0.19% 141
2014
Q2
$45.5M Buy
513,844
+103,000
+25% +$9.91M 0.12% 220
2014
Q1
$38.6M Buy
410,844
+143,911
+54% +$14.7M 0.12% 210
2013
Q4
$30.2M Buy
266,933
+91,449
+52% +$8.25M 0.09% 275
2013
Q3
$13.8M Sell
175,484
-14,728
-8% -$1.08M 0.05% 454
2013
Q2
$12.5M Buy
+190,212
New +$12.3M 0.04% 493

Other funds holding UTHR

Cliff Asness's UTHR Position: Q2 2026 in Review

Cliff Asness reduced its United Therapeutics (UTHR) stake by 34% in Q2 2026, selling an estimated $158M and leaving 546,002 shares worth $295M. The position accounts for 0.1% of the portfolio, ranked #272.

Cliff Asness first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $625M in Q4 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Cliff Asness held 546,002 shares of United Therapeutics worth $295M as of Q2 2026.
  • Cliff Asness sold 280,224 United Therapeutics shares in Q2 2026, an estimated $158M.
  • United Therapeutics made up 0.1% of Cliff Asness's portfolio in Q2 2026, its #272 holding.
  • Cliff Asness first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Cliff Asness's United Therapeutics position peaked at $625M in Q4 2025.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.